Adaptive Q2 MRD revenue up 42%, achieves MRD profitability; raises FY guidance

Adaptive Biotechnologies Corp

2025-Q2 EPS reported -$0.37 revenue$111,322,000

Total revenue $58.9M (+36% YoY); MRD revenue $49.9M (+42% YoY); MRD Adjusted EBITDA positive $1.9M.
clonoSEQ volume 25,321 (+37% YoY); Immune Medicine revenue $8.9M (+13% YoY).
Net loss $25.6M ($46.2M in Q2 2024); Adjusted EBITDA loss $7.2M vs $21.4M prior year.
FY 2025 MRD revenue guidance raised to $190-200M (from $180-190M); cash burn guidance lowered to $45-55M.
Cash $222M; launched clonoSEQ integration into Flatiron OncoEMR; recognized $5.5M pharma milestone revenue.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.